Cargando…

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer

The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Jian, Zhao, Jinou, Ni, Xudong, Gan, Hualei, Wei, Yu, Wu, Junlong, Zhang, Tingwei, Wang, Qifeng, Freedland, Stephen J., Wang, Beihe, Song, Shaoli, Ye, Dingwei, Liu, Chang, Zhu, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718110/ https://www.ncbi.nlm.nih.gov/pubmed/36209367 http://dx.doi.org/10.1002/1878-0261.13320

Ejemplares similares

Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer
por: Liu, Chang, et al.
Publicado: (2020)

Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity
por: Wei, Yu, et al.
Publicado: (2023)

Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study
por: Jin, Shengming, et al.
Publicado: (2020)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
por: Wu, Junlong, et al.
Publicado: (2017)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Combination of body mass index and albumin predicts the survival in metastatic castration‐resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials
por: Pan, Jian, et al.
Publicado: (2021)

Presence of CD133‐positive circulating tumor cells predicts worse progression‐free survival in patients with metastatic castration‐sensitive prostate cancer
por: Yang, Yunjie, et al.
Publicado: (2022)

Fat Attenuation Index of Renal Cell Carcinoma Reveals Biological Characteristics and Survival Outcome
por: Wang, Hongkai, et al.
Publicado: (2022)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
por: Wang, Beihe, et al.
Publicado: (2019)

Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study
por: Johnston, Ashley W., et al.
Publicado: (2020)

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients
por: Zhu, Sha, et al.
Publicado: (2021)

Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma
por: Wang, Beihe, et al.
Publicado: (2017)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Prognosis of Patients With Testicular Carcinoma Is Dependent on Metastatic Site
por: Xu, Peihang, et al.
Publicado: (2020)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
por: Giridhar, Karthik V., et al.
Publicado: (2018)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
por: Moreira, Daniel M., et al.
Publicado: (2015)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancer
por: Zhang, Tingwei, et al.
Publicado: (2023)

microRNAs and next generation sequencing for the prognosis of the metastatic melanoma
por: Pinto, Rosamaria, et al.
Publicado: (2015)

The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2021)

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)
por: Zhu, Yao, et al.
Publicado: (2020)

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD
por: de Wit, Ronald, et al.
Publicado: (2022)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
por: Mitsui, Yozo, et al.
Publicado: (2023)

A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
por: He, Dalin, et al.
Publicado: (2019)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
por: Wengel Mogensen, Søren, et al.
Publicado: (2016)

Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea
por: Kim, Yoonjung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ososgud2fg603prvglngefikd4